New Risk • Dec 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$557.8k market cap, or US$402.4k). Minor Risk Share price has been volatile over the past 3 months (19% average weekly change). Tillkännagivande • Dec 05
Vaxil Bio Ltd. announced that it has received CAD 0.14 million in funding On December 4, 2025, Vaxil Bio Ltd. closed the transaction. The company issued 1,244,441 units at a price CAD 0.1125 per Unit to raise gross proceeds of up to CAD 139,999.6125. Each warrant is exercisable, at any time prior to December 2, 2030. In accordance with applicable Canadian securities law, the securities issued pursuant to the Private Placement are subject to a four month and one day hold period expiring on April 3, 2026. The company compensated certain finders by payment of finders’ fees in the aggregate amount of CAD 11,200 and the issuance of an aggregate of 99,555 finders’ warrants. The finders’ warrants have identical terms to those of the warrants. Tillkännagivande • Dec 04
Vaxil Bio Ltd. Announces Board Changes Vaxil Bio Ltd. announces that Mr. Ari Kellen and Mr. Shawn Langer have resigned from the Company’s Board of Directors, effective immediately. Also effective immediately, the Company announces the appointment of Mr. Simon Igelman to the Company’s board. Mr. Igelman is a corporate transactional lawyer. His practice focuses on corporate finance and mergers and acquisitions, as well as providing advice on structured finance and capital markets mandates. Mr. Igelman has represented private and public companies on a variety of transactions, including private placements of equity and debt securities, securitizations in a variety of asset classes, public and private acquisitions and general corporate and commercial law matters. Tillkännagivande • Oct 30
Vaxil Bio Ltd. announced that it expects to receive CAD 0.35 million in funding Vaxil Bio Ltd. announced a non brokered private placement to issue 2,456,140 units at an issue price of CAD 0.1425 for the proceeds of CAD 350,000 on October 29, 2025. Each Unit will consist of one common share of the Company ("Shares") and one common share purchase warrant of the Company ("Warrants"). Each Warrant will entitle the holder to acquire one Share at a price of CAD 0.19 per Share for a period of five years following the closing of the Offering. The closing of the Offering is subject to a number of conditions, including but not limited to, approval by the TSX Venture Exchange of the Offering. The Company expects the Offering to close on or around November 14, 2025. On the closing of the Offering, the Company has agreed to pay certain finders a cash commission of up to 8% of the gross proceeds of the Offering and non-transferrable Warrants. The Units, the Shares and Warrants comprising the Units and the Finders' Warrants will be subject to a hold period of four months and one day from their date of issue in accordance with applicable securities laws. Tillkännagivande • Apr 04
Vaxil Bio Ltd. Announces Appointment of Daniel Bloch to the Audit Committee Vaxil Bio Ltd. announced the Mr. Daniel Bloch, a current director of the Company has joined the audit committee, effective immediately. The audit committee now comprises Dr. Ari Kellen, Dr. Shawn Langer and Mr. Daniel Bloch, all independent directors. The board of directors remains unchanged, and comprises Mr. Gadi Levin (Chairperson and CEO), Dr. Ari Kellen (independent director), Dr. Shawn Langer (independent director) and Mr. Daniel Bloch (independent director). Tillkännagivande • Jan 17
Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction. Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. On August 20, 2024, the companies entered into an amalgamation agreement pursuant to which Vaxil will acquire all of the issued and outstanding securities of Green Data in a reverse merger transaction. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data.
Green Data Center Real Estate Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on January 16, 2025. Tillkännagivande • Oct 07
Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024 Vaxil Bio Ltd., Annual General Meeting, Dec 12, 2024. Board Change • Jul 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Special Advisor to the Board Michael Berelowitz was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Board Change • Jun 04
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Special Advisor to the Board Michael Berelowitz was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • May 28
Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction. Green Data Center Real Estate Inc. entered into a letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on May 25, 2024. The transaction is subject to regulatory body, both companies board of directors, due diligence, definitive agreement, shareholder approval, obtaining financing and have a minimum of cash and cash equivalents of CAD 1 million at the date of closing of the transaction. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of 5 directors, a majority of whom shall be nominated by Green Data. The nominees of Green Data are expected to consist of Jason Bak, Simon Lee, Mark Goodman and Gadi Levin, with the remaining board nominees to be determined prior to Closing. The parties expect Jason Bak to act as CEO. 5X Capital Management acted as financial advisor to Green Data. Tillkännagivande • Mar 06
Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction. Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration.
The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI.
Copper Bullet Mines Inc. cancelled the acquisition of Vaxil Bio Ltd. (TSXV:VXL) in a reverse merger transaction on March 4, 2024. Tillkännagivande • Jan 11
Copper Bullet Mines Inc. entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction. Copper Bullet Mines Inc. ("CBMI") entered into a non-binding letter of intent to acquire Vaxil Bio Ltd. (TSXV:VXL) for CAD 15.8 million in a reverse merger transaction on January 9, 2024. Pursuant to the Transaction, one Vaxil consolidated share will be issued to the holders of CBMI Shares in exchange for each one CBMI Share issued and outstanding as at the effective date of the Transaction. It is expected that prior to the closing of the transaction Vaxil will divest all existing assets except cash to unrelated third parties. Upon completion of the Transaction, the Resulting Issuer will carry on the business of CBMI. As a condition to closing the Transaction, concurrently with, or immediately prior to Closing, and subject to Vaxil shareholder approval, Vaxil will undertake a share consolidation, which is anticipated to be a consolidation ratio of 1:16.3557. Upon completion of the Transaction, it is expected that the former shareholders of CBMI will hold approximately 65.64% of the shares of the Resulting Issuer (on a non-diluted basis), the former shareholders of Vaxil will hold approximately 17.05% of the Resulting Issuer Shares, the Subscription Receipts holders will hold approximately 15.27% of the Resulting Issuer Shares and the Finder will hold approximately 2.04% of the Resulting Issuer Shares. Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer shall consist of a minimum of three and a maximum of ten directors, a majority of whom shall be nominated by CBMI. The nominees of CBMI are expected to consist of, at a minimum, Daniel Weir, Mohamad Basim Anwer, Erika Dohring, Doug Harris, Keith Minty and Gadi Levin. The parties expect Daniel Weir to act as CEO Arif Shivji to act as CFO and Dr. Michael Feinstein to be VP Exploration.
The Transaction is subject to requisite regulatory approval, including the approval of the TSXV, and standard closing conditions, including the approval of the directors of each of Vaxil and CBMI of the Definitive Agreement, completion of due diligence investigations to the satisfaction of each of Vaxil and CBMI, completion of CBMI brokered private placement, Vaxil and CBMI enter into definitive agreement, shareholder approvals, consolidation of Vaxil shares. Bayline Capital Partners is acting as financial advisor to CBMI. Board Change • Jan 06
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director & Member of Scientific Advisory Board Ari Kellen was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 05
Vaxil Bio Ltd. Provides an Update on the Results of in Vivo Efficacy Study for Licensed P-Esbp-DOX VAXIL BIO LTD. provided an update on the results of in vivo efficacy study for licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in press release from October 12, 2021. Vaxil, together with Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev (BGU), have demonstrated therapeutic success by prolonging the survival of mice treated with P-Esbp-DOX in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). The results of the current in vivo experiment, along with the previous in vivo experiments suggests that P-Esbp-DOX which combines the safe HPMA polymer, the high affinity E-selectin targeting peptide, and the commonly used chemotherapeutic drug doxorubicin, is a promising targeted drug delivery system for the treatment of aggressive metastatic cancer. P-Esbp-DOX is an HPMA (N-(2-hydroxypropyl methacrylamide)) polymer conjugated with a high-affinity E-selectin-binding peptide and with the cytotoxic drug doxorubicin (DOX). Targeting E-selectin is relevant to diseases with inflammatory component and cancer, since E-selectin is expressed exclusively on inflamed blood vessels and play an important role in the development of inflammation, cancer and supports metastatic spread of cancer. Prof. Ayelet David’s previous work in cancer research demonstrated that a single dose therapy of P-Esbp-DOX is effective in decreasing the rate of tumor growth and prolonging the survival of mice bearing primary Lewis lung carcinoma (3LL) tumors and established melanoma (B16-F10) lung metastases. In the experiment, four groups of mice were treated, four days post intrasplenic inoculation of CT26 colorectal cancer cells, with a single dose of either P-Esbp-DOX or P-DOX (15 mg/kg DOX equivalence), or free DOX (8 mg/kg), or saline. The findings confirm the significant effectiveness of a single dose of P-Esbp-DOX over other treatments in mice with detected CRC liver metastases: The number of surviving mice at day 85 was: 3/7 (43%) for P-Esbp-DOX, 1/6 (17%) for free DOX, and 0/6 for P-DOX and saline. The survival medians were: 63 days for P-Esbp-DOX, 36.5 days for P-DOX, 30 days for free DOX, and 35 days for saline (p=0.003 for P-Esbp-DOX vs. control P-DOX). P-Esbp-DOX was well-tolerated at the dose administered, with no weight loss observed post treatment. In summary, this experiment, coupled with previous work, continues to demonstrate the important role this novel therapeutic approach could play in cancer at all stages. Vaxil is pursuing all necessary steps to initiate human clinical trials as soon as possible. As previously disclosed in the Company's press release from August 28, 2019, the Company entered into an exclusive worldwide license agreement for the development and commercialization of a targeted cancer therapy with BGN Technologies, the technology transfer company of BGU. To the extent that a successful therapy is developed, the Company will pay BGU a royalty on sales. Tillkännagivande • Mar 12
Vaxil Bio Ltd. Announces 2021 Reseach and Development Strategy and Progress VAXIL BIO LTD. announced the direction and progress of its 2021 research strategy. Vaxil's strategy remains focused on delivering long-term value based on the unique benefits of signal peptides ("SPs") including their broad and robust immune response, both cellular and humoral, their reduced sensitivity to genetic mutation and manufacturing efficiency. Vaxil's has initiated experimental work in the following areas of its 2021 strategic focus: Optimizing the immune response to SPs in infectious diseases such as COVID, as well as oncology, to demonstrate the robust and consistent value SPs can bring to the clinic; Developing oral delivery technology internally as well as through relevant partnerships, to expand value across all therapeutic areas; Preparing for a clinical trial that both leverages Vaxil's science and previous success in its research programs and creates the best opportunity for helping patients. Consistent with this strategy, the company has initiated efforts to design and then conduct experiments focused on strengthening the value proposition of SPs across these therapeutic areas by demonstrating the ability to generate a robust
and consistent immune response. Based on the previously announced positive signs seen in an early oral delivery experiment, the Company is proceeding to design and conduct formulation experiments that further validate oral routes of administration. Vaxil will also explore partnerships that can maximize the likelihood of successfully delivering SPs orally. Finally, building on previous successful investigation, the Company has begun efforts to accelerate the pathway to a clinical trial through the design and execution of supportive experiments. In 2021, the Company will continue to refine its work on the potential COVID-19 vaccine, building on the data and results from 2020, which can also be a model for other infectious diseases. Consistent with the work performed during 2020 in COVID, the Company is also pleased to announce that it has submitted an international patent application for its anti-infective vaccine platform, specifically for a coronavirus vaccine that is intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing an infectious disease as well as methods for producing a peptide vaccine against coronaviruses. The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time. Tillkännagivande • Feb 18
Vaxil Bio Ltd. Provides Strategy Update from Conclusion of Covid-19 Challenge Study VAXIL BIO LTD. reports results of the previously disclosed COVID-19 vaccine candidate challenge experiment and the strategy going forward. Vaxil established the USAMRIID collaboration (CRADA) based on the global need for a viable COVID-19 vaccine utilizing an alternative technology that demonstrates cellular and humoral responses, both of which are necessary. In this rapidly moving pandemic, variants have become the established infection model, which can be better addressed with Vaxil’s SP approach. Neutralizing antibody technologies may require frequent modifications while Vaxil’s signal peptide (“SP”) technology may provide long-term efficacy as the virus mutates. The USAMRIID COVID-19 mouse model challenge experiment demonstrated that Vaxil’s SP-based vaccine candidate generated a specific immune response. This was not, however, accompanied by vaccine protection of the animals. The Company plans to conduct additional analyses and on the basis of the understanding obtained, refine aspects of experiment design, including dosing levels and regimens, and alternate animal models that may allow future investigation of the unique and specific aspects of SP’s as immunogens. In addition, the Company will evaluate alternate peptide delivery approaches, including oral administration. This strategy focuses future efforts on the unique benefits of SP’s to sustain Vaxil’s competitive advantage over the longer term, beyond the current crisis environment, when it can realistically achieve approval for human use. The Company’s strategy to deliver value over the long-term is based on potentially unique benefits of SPs including their broad and strong immune response, both cellular and humoral, their reduced propensity to genetic mutation and the advantage of efficient manufacturing. Tillkännagivande • Feb 02
VAXIL BIO LTD. Appoints Michael Berelowitz as Special Advisor to its Board VAXIL BIO LTD. Announced that Dr. Michael Berelowitz has been appointed as special advisor to its board. Dr. Michael Berelowitz, formerly Pfizer's Head of Clinical Development and Medical Affairs (Specialty Care), has enjoyed a 50+ year career in the biomedical sciences across the clinical practice of medicine, basic and clinical research and teaching, along with senior responsibilities in administration, budget management, and people leadership in academia and pharmaceutical companies/industry settings. Michael has also served on company boards, including public companies. Is New 90 Day High Low • Dec 31
New 90-day high: CA$0.24 The company is up 109% from its price of CA$0.12 on 01 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 7.0% over the same period. Tillkännagivande • Dec 30
VAXIL BIO LTD. Provides Update on USAMRIID and Oral Experiments VAXIL BIO LTD. announced that further to company's press release dated December 3, 2020, in respect to company's cooperative research and development agreement (CRADA) with US Army Medical Research Institute of Infectious Diseases (USAMRIID), the mice have received two of the three scheduled vaccinations. The third and final vaccine is scheduled to be administered later this week. USAMRIID reports that the mice appear to be fine having responded normally to the injections administered to date and that the experiment is proceeding on schedule. The Company expects that the mice will be challenged with the COVID-19 virus in mid-January 2021, after having had the chance to develop an immune response. Vaxil expects to provide a further update at the beginning of February 2021. In addition, The Company reported that it initiated an exploratory pre-clinical study to determine the viability of oral administration. This experiment remains on schedule, having completed the first three doses successfully. Vaxil anticipates reporting results in late January 2021. The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time. Tillkännagivande • Dec 04
Vaxil Bio Ltd. Provides Business Update on Corvax Experiments VAXIL BIO LTD. announced that further to press release dated October 26, 2020, in respect to cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases, the company has completed the manufacturing of Corvax product for this research project, which is expected to arrive at USAMRIID by the end of this week. The Company further notes that it has initiated an exploratory pre-clinical study to determine the viability of administering Corvax orally. Results from this work are anticipated in January 2021. Tillkännagivande • Nov 10
Vaxil Bio Ltd. announced that it expects to receive CAD 1.5 million in funding Vaxil Bio Ltd. (TSXV:VXL) announced a non-brokered private placement of 20,000,000 units at a price of CAD 0.075 per unit for the gross proceeds of CAD 1,500,000 on November 9, 2020. The transaction will include participation from certain directors and officers of the company. Each unit will consists of one common share and one common share purchase warrant. Each warrant shall entitle the holder to acquire one common share at a price of CAD 0.10 per common share for a period of three years from the closing. The Company expects to pay a finder’s fee equal to 7% of the gross proceeds of the Private Placement and additional compensation for acting as a finder in respect of the Private Placement, the company will issue to finders, selling compensation unit warrants equal to 7% of the aggregate number of Units sold by such finders in the Private Placement. The Finders Warrants will be exercisable into an equal number of Units, at an exercise price equal to CAD 0.10 per Unit, for a period of 2 years following the Closing Date. The transaction is subjected to a statutory hold period of four months plus one day from the date of issuance, in accordance with applicable securities legislation. The Company anticipates that the Private Placement will close on or about November 23, 2020. Tillkännagivande • Oct 27
Vaxil Enters into a Cooperative Research and Development Agreement with U.S. Army Medical Research Institute of Infectious Diseases ('USAMRIID') VAXIL BIO LTD. announced that on October 26, 2020, it has entered into a cooperative research and development agreement (CRADA) with USAMRIID under which USAMRIID will test CorVax™ for its ability to specifically prevent COVID-19 in mice. Vaxil recently reported that its CorVax™ successfully generated an immune response in the experiment carried out at the Allergy and Clinical Immunology Unit at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel by Dr. David Hagin. As a result, the Company is progressing to the next study to test whether this immune response is specific enough to COVID-19 to provide protection against the virus in a mouse model. The work to be performed by USAMRIID will be financed out of the Company’s existing working capital, according to David Goren, Vaxil’s Chairman and Chief Executive Officer. The team hopes to secure additional funding for future studies. Tillkännagivande • Oct 14
Vaxil Bio Ltd. Initiates Pre-Clinical Study in New Oncology Target VAXIL BIO LTD. announced the initiation of the pre-clinical program for ImMucin™ in combination with the E-selectin binding polymer-based therapeutic, which Vaxil licensed for development and commercialization from BGN Technologies, the technology transfer company of Ben-Gurion University of the Negev, Israel (“BGU”). The pre-clinical program will be led by Prof. Ayelet David from BGU to assess the potential for ImMucin and the P-Esbp separately and in combination for the treatment of solid tumors including breast and ovarian cancer. P-Esbp was invented by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology, Prof. Gonen Ashkenasy from the Department of Chemistry and their joint PhD student, Yosi Shamay, all from the BGU. P-Esbp has been shown to interfere with E-selectin-mediated interactions, thus blocking leukocyte and cancer cells recruitment to inflamed and cancerous tissues, which reduced colonization of circulating cancer cells in secondary organs. In addition, it was also shown to inhibit leukocyte recruitment and inflammation in animal models of liver injury and atherosclerosis. These results combined demonstrate the promising therapeutic potential of E-selectin targeted therapy for inhibiting inflammation and arresting cancer disease progression as well as other diseases where inflammation plays a role. The work performed by Prof. David at BGU will be supported by the Company’s existing working capital. Tillkännagivande • Jul 20
Vaxil Bio Ltd.(TSXV:VXL) dropped from S&P/TSX Venture Composite Index Vaxil Bio Ltd.(TSXV:VXL) dropped from S&P/TSX Venture Composite Index 
